<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346877</article-id>
      <article-id pub-id-type="pmc">3875989</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132280</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Calciphylaxis: a rare but potentially fatal event of chronic kidney
disease. Case report<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Calcifilaxia: complica&#xE7;&#xE3;o rara, mas potencialmente fatal da doen&#xE7;a renal
cr&#xF4;nica. Relato de caso</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Marques</surname>
            <given-names>Silvio Alencar</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kakuda</surname>
            <given-names>Aline Cruz</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Menda&#xE7;olli</surname>
            <given-names>Thais Jung</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abbade</surname>
            <given-names>Luciana P. Fernandes</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marques</surname>
            <given-names>Mari&#xE2;ngela Esther Alencar</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, PhD. Department of Dermatology and Radiotherapy. Botucatu Medical
School, S&#xE3;o Paulo State University "J&#xFA;lio de Mesquita Filho" (FMB-Unesp) - Botucatu
(SP), Brazil.</aff>
      <aff id="aff02"><label>2</label> MD, Dermatologist. Member of the Brazilian Society of Dermatology.
Private clinic - S&#xE3;o Paulo (SP) - Brazil.</aff>
      <aff id="aff03"><label>3</label> MD, PhD. Department of Dermatology and Radiotherapy. Botucatu Medical
School, S&#xE3;o Paulo State University "J&#xFA;lio de Mesquita Filho" (FMB-Unesp) - Botucatu
(SP), Brazil.</aff>
      <aff id="aff04"><label>4</label> MD, PhD. Department of Pathology. Botucatu Medical School, S&#xE3;o Paulo
State University "J&#xFA;lio de Mesquita Filho" (FMB-Unesp) - Botucatu (SP), Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Silvio Alencar Marques, Departamento de Dermatologia e
Radioterapia -Faculdade de Medicina, Distrito de Rubi&#xE3;o Junior S/N - Botucatu,
18618-970 - S&#xE3;o Paulo - SP, Brazil. E-mail: <email>smarques@fmb.unesp.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>44</fpage>
      <lpage>47</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>12</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Calciphylaxis or calcific uremic arteriolopathy is a rare cutaneous-systemic disease
occurring in patients with advanced chronic kidney disease. The classical clinical
picture is that of a necrotic and progressive skin ulcer of reticular pattern, mostly
in the lower legs and susceptible to local infection. It is a product of mural
calcification and occlusion of cutaneous and sub-cutaneous arteries and arterioles.
The authors report the case of a 73-year-old male patient in his late stage of renal
disease presenting severe necrotic cutaneous ulcers on lower legs followed by local
and systemic infection and death due to sepse after parathyroidectomy.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Calcifilaxia ou arteriolopatia ur&#xEA;mica calcificante &#xE9; quadro cut&#xE2;neo-sist&#xEA;mico raro
em paciente com doen&#xE7;a renal cr&#xF4;nica em fase de di&#xE1;lise. Caracteriza-se por &#xFA;lcera
cut&#xE2;nea, necrose de padr&#xE3;o retiforme, evolu&#xE7;&#xE3;o progressiva, localizada principalmente
nos membros inferiores e suscetibilidade &#xE0; infec&#xE7;&#xE3;o secund&#xE1;ria. Decorre de
calcifica&#xE7;&#xE3;o da parede arterial e oclus&#xE3;o de arter&#xED;olas e art&#xE9;rias cut&#xE2;neas e
subcut&#xE2;neas. Os autores relatam caso de paciente do sexo masculino de 73 anos de
idade com doen&#xE7;a renal em estadio tardio e &#xFA;lceras cut&#xE2;neas nos membros inferiores
com necrose, evolu&#xE7;&#xE3;o grave, infec&#xE7;&#xE3;o local e sist&#xEA;mica e, &#xF3;bito por sepse ap&#xF3;s
paratireoidectomia</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Calciphylaxis</kwd>
        <kwd>Kidney failure, chronic</kwd>
        <kwd>Leg ulcer</kwd>
        <kwd>Skin ulcer</kwd>
        <kwd>Vascular calcification</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Calciphylaxis or calcific uremic arteriolopathy is a rare cutaneous-systemic disease
occurring, most frequently, in patients in the late stage of chronic kidney
disease.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>The terminology
"calciphylaxis" was introduced by Selye in 1961, based on his experience of promoting
vascular calcification in animal model as a consequence of anaphylactic reactions, using
hyperparathyroidism and hypervitaminosis D as sensitization factor and trauma, among
others, as a challenging factor.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref></sup>Although what was described by Selye as
"calciphylaxis" in rodents does not fit exactly that observed in patients, the term
calciphylaxis has been used since them to describe a syndrome with rapid subcutaneous
tissue calcification and cutaneous necrosis in patients with chronic renal disease. Its
synonym "calcific uremic arteriolopathy" is an adequate descriptive term, even though
the disease can occur in patients with normal renal function.<sup><xref ref-type="bibr" rid="r03">3</xref></sup>Calciphylaxis has been reported to occur in 1% to 4.5% of
patients in dialysis, mostly in hemodialysis, with preponderance in patients who are
obese, diabetic, present liver disease, are using systemic corticosteroids or have a
calcium-phosphate product of more than 70mg<sup>2</sup>/dL<sup>2</sup>.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup>
The classical clinical picture is that of an initial skin lesion, livedo
reticularis-like on the lower limbs, which progress to violaceous, painful, plaque or
subcutaneous nodules, followed by ischemic/necrotic ulcers of reticular
pattern.<sup><xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup> Usually, the patients present hyperphosphatemia,
hyperparathyroidism and an elevated plasma calcium and phosphate product. </p>
      <p>We describe the case of a 74-year-old male patient with end-stage renal disease
requiring peritoneal dialysis that developed severe, progressive calciphylaxis on both
lower distal limbs, eventually fatal. </p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>The patient was referred from a nephrological unit with a two-week history of painful
cutaneous plaques soon followed by necrotic ulcers on both lower limbs. He had been in
peritoneal dialysis for five years due to a chronic hypertension-related kidney disease.
On physical examination a necrotic ulcer of 3 cm diameter with a reticular area of
purpuric lesion was present on both limbs (<xref ref-type="fig" rid="f01">Figure
1</xref>). Laboratory investigation showed elevated plasma levels of calcium,
phosphate, (Ca<sup>+</sup>x P<sup>+</sup>= 66,7mg<sup>2</sup>/dl<sup>2</sup>),
parathormone, alkaline phosphatase and C-reactive protein. Calciphylaxis was diagnosed
based on clinical, radiological and histological data and antibiotics, diet regimen to
reduce calcium and phosphate balance plus local hydrogel dressing were prescribed (<xref ref-type="fig" rid="f02">Figure 2</xref>-<xref ref-type="fig" rid="f05">5</xref>).
Regardless of therapeutic support the lesions progressed into necrotic ulcer of
phagedenic pattern (<xref ref-type="fig" rid="f06">Figure 6</xref>). Following the
failure of clinical approach an extensive surgical debridement was performed associated
with new antibiotics plus intensive local dressing. Despite such procedures the lesion
progressed, the clinical condition worsened and eventually the patient was submitted to
a parathyroidectomy but he died few days later due to septic shock. </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Calciphylaxis: necrotic ulcer with purpuric halo and reticulate pattern of lesion
on the leg</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0044-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Calciphylaxis: progression of lesion with large area of necrosis on reticulate
pattern</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0044-g02"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Calciphylaxis: higher power view of calcium deposit on the arteriole wall (H.E. X
400)</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0044-g05"/>
      </fig>
      <fig id="f06" orientation="portrait" position="float">
        <label>FIGURE 6</label>
        <caption>
          <p>Calciphylaxis: late follow-up with extensive necrotic lesions</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0044-g06"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Calciphylaxis, once thought to be particularly rare, is becoming more frequent as the
number of patients requiring hemodialysis or peritoneal dialysis is more
prevalent.<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup>Although classically reported as associated to chronic
renal disease, calciphylaxis can be diagnosed in patients with cancer, inflammatory
bowel disease or presenting primary hyperparathyroidism with normal renal
function.<sup><xref ref-type="bibr" rid="r04">4</xref></sup>Even though the
etiopathogenesis is not well understood, abnormalities present in the uremic patient as
hyperphosphatemia, hyperparathyroidism, elevated plasma calcium and phosphate product,
active vitamin D supplementation and deficiency of vascular calcification inhibitors
have been implicated in the process.<sup><xref ref-type="bibr" rid="r04">4</xref>-<xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>The cutaneous lesions are described as the sudden development of tender, violaceous skin
lesion of livedoid or reticular pattern that progress to necrotic ulcerations, which
frequently become superinfected. These ulcers heal poorly and are very painful. Areas
commonly affected are the lower limbs and those with thick adipose tissue, such as the
breasts, abdomen and gluteal region. Besides the skin other organs and systems can be
involved as lung, heart, kidneys, skeletal muscle, tongue, pancreas and gastrointestinal
tract.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>The diagnosis can be based on clinical grounds, supported by histological analysis if
necessary. The laboratory workout must cover all the possible implications of chronic
kidney disease with special attention to Ca<sup>+</sup>and P<sup>+</sup>values and
evidence of skin or systemic infection. </p>
      <p>The treatment must focus on local wound care and metabolic control. It is essential to
prevent local and systemic infection. Wound care involves the use of enzymatic debriding
agents, hydrocolloid or hydrogel dressings, avoiding tissue trauma or excessive
manipulation and prescribing systemic antibiotics as needed.<sup><xref ref-type="bibr" rid="r05">5</xref>-<xref ref-type="bibr" rid="r07">7</xref></sup>Surgical
debridement is controversial due to increased risk of sepsis and worsening
pain.<sup><xref ref-type="bibr" rid="r07">7</xref></sup>As calciphylaxis is a very
painful and debilitating disease nutritional and psychological support as well as
specialized pain management must be provided. Efforts must be made to correct the plasma
calcium and phosphorus concentrations in order to achieve a calcium and phosphorus
product below 55.0 mg<sup>2</sup>/dl<sup>2</sup> and serum levels of phosphate between
2.7 mg/dl and 4.6 mg/dl.<sup><xref ref-type="bibr" rid="r08">8</xref></sup>Normalization
of serum parathyroid hormone levels needs to be also a priority and some patients have
obtained improvement after being submitted to a parathyroidectomy. <sup><xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>Sodium thiosulfate has been proposed as a novel and efficient therapy for calciphylaxis
as marked improvements with reduction of pain, inflammation and healing of lesions have
been demonstrated within a few days to months of use.<sup>(2; 4; 8; 9)</sup>The
suggested mechanism of action is that it would dissolve the insoluble calcium salts
embedded in tissue. The doses vary from 5 g to 25 g given intravenously over 1 h after
high-flux hemodialysis three times a week for months.<sup><xref ref-type="bibr" rid="r04">4</xref></sup>
<sup>;</sup>
<sup><xref ref-type="bibr" rid="r08">8</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup>Bisphosphonates have also been proposed as effective in some
cases.<sup><xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>Calciphylaxis is reported to be a lethal complication with an estimated 1-year survival
rate of 45.8%. Mortality is usually reported as a result of local and systemic
infections and sepsis, similar to that observed in this present case report.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>Although uncommon, calciphylaxis must be known by dermatologist as early diagnosis and
proper management can be decisive for better prognosis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Work performed at the Department of Dermatology and Radiotherapy, Botucatu Medical
School, S&#xE3;o Paulo State University "J&#xFA;lio de Mesquita Filho" (FMB-Unesp) - Botucatu
(SP), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="financial-disclosure">
        <p>Financial Support: None</p>
      </fn>
      <fn id="fn03" fn-type="conflict">
        <p>Conflict of Interest: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandenburg</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Cozzolino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ketteler</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Calciphylaxis: a still unmet challenge</article-title>
          <source>J Nephrol</source>
          <year>2011</year>
          <volume>24</volume>
          <fpage>142</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="pmid">21337312</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandenburg</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Kramann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Specht</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ketteler</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Calciphylaxis in CKD and beyond</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2012</year>
          <volume>27</volume>
          <fpage>1314</fpage>
          <lpage>1318</lpage>
          <pub-id pub-id-type="pmid">22344774</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roncada</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Abreu</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Nai</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>DF</given-names>
            </name>
          </person-group>
          <article-title>Calciphylaxis, a diagnostic and therapeutic challenge: report of a
successful case</article-title>
          <source>An Bras Dermatol</source>
          <year>2012</year>
          <volume>87</volume>
          <fpage>752</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="pmid">23044570</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayden</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sowers</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Khanna</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Calciphylaxis: calcific uremic arteriolopathy and the emerging role of
sodium thiosulfate</article-title>
          <source>Int Urol Nephrol</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>443</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="pmid">18369733</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Panuncialman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Falanga</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Unusual causes of cutaneous ulceration</article-title>
          <source>Surg Clin North Am</source>
          <year>2010</year>
          <volume>90</volume>
          <fpage>1161</fpage>
          <lpage>1180</lpage>
          <pub-id pub-id-type="pmid">21074034</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goel</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Bellovich</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>McCullough</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Treatment of severe metastatic calcification and calciphylaxis in
dialysis patients</article-title>
          <source>Int J Nephrol</source>
          <year>2011</year>
          <volume>2011</volume>
          <fpage>701603</fpage>
          <lpage>701603</lpage>
          <pub-id pub-id-type="pmid">21423552</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bishop</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Podesta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Troy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>XE</given-names>
            </name>
          </person-group>
          <article-title>Surgical management of calciphylaxis. associated with primary
hyperparathyroidism. A Case report and review of the literature</article-title>
          <source>Int J Endocrinol</source>
          <year>2010</year>
          <volume>2010</volume>
          <comment>pii: 823210</comment>
          <pub-id pub-id-type="doi">10.1155/2010/823210</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ross</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Evolution of treatment strategies for calciphylaxis</article-title>
          <source>Am J Nephrol</source>
          <year>2011</year>
          <volume>34</volume>
          <fpage>460</fpage>
          <lpage>467</lpage>
          <pub-id pub-id-type="pmid">21986387</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayden</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Sodium thiosulfate: new hope for the treatment of
calciphylaxis</article-title>
          <source>Semin Dial</source>
          <year>2010</year>
          <volume>23</volume>
          <fpage>258</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="pmid">20636917</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torregrosa</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Dur&#xE1;n</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Barros</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Blasco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arias</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cases</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>X. Successful treatment of calcific uraemic arteriolopathy with
bisphosphonates</article-title>
          <source>Nefrologia</source>
          <year>2012</year>
          <volume>32</volume>
          <fpage>329</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="pmid">22592420</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f03" orientation="portrait" position="float">
      <label>FIGURE 3</label>
      <caption>
        <p>Calciphylaxis: computed tomography of legs showing calcification of posterior tibial
artery (arrow)</p>
      </caption>
      <graphic xlink:href="abd-88-06-s1-0044-g03"/>
    </fig>
    <fig id="f04" orientation="portrait" position="float">
      <label>FIGURE 4</label>
      <caption>
        <p>Calciphylaxis: subcutaneous arteriole with calcium deposit on the wall and
proliferation of endothelial cells. (H.E. X 200)</p>
      </caption>
      <graphic xlink:href="abd-88-06-s1-0044-g04"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
